Scientists at Institute of Nano Science and Technology (INST), Mohali, an autonomous institute of the Department of Science and Technology (DST) Researchers have recently developed a groundbreaking drug delivery method that effectively treats Central Nervous System Tuberculosis (CNS-TB)—a severe and often deadly form of tuberculosis affecting the brain. This innovation addresses a critical challenge in treating CNS-TB: the blood-brain barrier (BBB), which inhibits the effectiveness of many conventional TB medications.
The unique method involves using nasal delivery to administer chitosan nanoparticles, which are biocompatible and biodegradable. These nanoparticles encapsulate potent anti-tuberculosis drugs, specifically isoniazid (INH) and rifampicin (RIF), and are designed to form nano-aggregates that facilitate easy nasal administration.
The research conducted by the Institute of Nano Science and Technology (INST) in Mohali also suggests potential extensions of this technology to develop targeted therapies that could effectively deliver medications to the brain, enhancing treatment efficacy and reducing side effects commonly associated with traditional systemic administration methods.
The introduction of chitosan nanoparticles for nasal delivery marks a significant advancement in the fight against CNS-TB, addressing previous limitations posed by the blood-brain barrier and potentially revolutionizing the treatment strategies for a variety of neurological conditions in the future.
Source